Clinical Research

Thumbnail

Too much screen time is bad for the heart

The excessive use of electronic devices is associated with significant health risks for young children and adolescents. In fact, too much screen time may impact the body in ways that last well into adulthood. 

stroke brain dementia alzheimer's puzzle mental health

MRI findings may signal patients' receptiveness to different mental health treatment methods

Differences in connectivity patterns could reveal which patients are most likely to respond positively to self-guided therapy.

COVID significantly increases risk of death from metastatic cancer, new study shows

Viruses like COVID-19 and the flu could awaken dormant cancer cells that have previously spread to the lungs, triggering growth of metastatic disease.

MRI biomarkers predict cognitive impairment post-stroke

MRI biomarker could identify patients at risk of cognitive decline post-stroke

A new study’s findings highlight the potential for imaging biomarkers to help guide post-stroke care decisions in the future. 

ESC Congress 2022 European Society of Cardiology

The most anticipated trials at ESC 2025

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.

Tirzepatide, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1), has been approved by the U.S. Food & Drug Administration (FDA) for improving glycemic control among adults with type 2 diabetes. The medication, sold by Eli Lilly and Company under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

Tirzepatide demonstrates cardiovascular protection in head-to-head trial with dulaglutide

Tirzepatide met the primary endpoint of non-inferiority versus dulaglutide, with an 8% lower rate of MACE events included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight.

PCI

Pilot study looks at same-day discharge PCI for acute coronary syndromes

Study shows same-day discharge is feasible for carefully selected, uncomplicated ACS patients. 

pharmaceutical drug approval process

New drug candidate for AFib fails in first-in-human trial—in fact, it made matters worse

Researchers had thought 2-HOBA might reduce the risk of AFib recurrence after catheter ablation procedures. What they found, however, was that treatment with the compound was actually harmful for patients instead of helpful.